Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma

in European Journal of Endocrinology
Correspondence should be addressed to M Kroiss or M Kunz; Email: Kroiss_M@ukw.de or meik.kunz@uni-wuerzburg.de

*(S Schweitzer and M Kunz contributed equally to this work)

Restricted access

48-hour access to this article

USD $30.00

Objective

Current workup for the pre-operative distinction between frequent adrenocortical adenomas (ACAs) and rare but aggressive adrenocortical carcinomas (ACCs) combines imaging and biochemical testing. We here investigated the potential of plasma steroid hormone profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) for the diagnosis of malignancy in adrenocortical tumors.

Design

Retrospective cohort study of prospectively collected EDTA-plasma samples in a single tertiary reference center.

Methods

Steroid hormone profiling by liquid chromatography tandem mass spectrometry (LC-MS/MS) in random plasma samples and logistic regression modeling.

Results

Fifteen steroid hormones were quantified in 66 ACAs (29 males; M) and 42 ACC (15 M) plasma samples. Significantly higher abundances in ACC vs ACA were observed for 11-deoxycorticosterone, progesterone, 17-hydroxyprogesterone, 11-deoxycortisol, DHEA, DHEAS and estradiol (all P < 0.05). Maximal areas under the curve (AUC) for discrimination between ACA and ACC for single analytes were only 0.76 (estradiol) and 0.77 (progesterone), respectively. Logistic regression modeling enabled the discovery of diagnostic signatures composed of six specific steroids for male and female patients with AUC of 0.95 and 0.94, respectively. Positive predictive values in males and females were 92 and 96%, negative predictive values 90 and 86%, respectively.

Conclusion

This study in a large adrenal tumor patient cohort demonstrates the value of plasma steroid hormone profiling for diagnosis of ACC. Application of LC-MS/MS analysis and of our model may facilitate diagnosis of malignancy in non-expert centers. We propose to continuously evaluate and improve diagnostic accuracy of LC-MS/MS profiling by applying machine-learning algorithms to prospectively obtained steroid hormone profiles.

 

Official journal of

European Society of Endocrinology

Sections

Figures

  • View in gallery

    Sex-specific steroid hormone patterns in ACA and ACC patients. Log2-transformed absolute quantity of the 15 steroid hormones 11-deoxycorticosterone (DOC), corticosterone (B), aldosterone (A4), progesterone (P4), 17OHP, 21-deoxycortisol (21-DF), 11-deoxycortisol (B), cortisol (F), cortisone (E), DHEA, DHEAS, androstenedione (A4), testosterone, DHT and estradiol (E2) as measured by LC-MS/MS in non-aldosterone-producing adrenocortical adenomas (ACAs) and adrenocortical carcinoma (ACC) patients. (A) In male, significantly increased quantities of 11DOC, A, P4, B and E2 were observed in ACC (right panel, n = 15) vs ACA left panel (n = 29). (B) Female patients showed increased 11DOC, P4, 17-OHP, DHEA, DHEAS and testosterone between ACC (n = 27) and ACA (n = 37). Steroids are color coded in green for mineralocorticoids and precursors, yellow glucocorticoids and precursors, red androgens and gray estradiol. The asterisks indicate P < 0.05.

  • View in gallery

    Optimal diagnostic signatures developed by logistic regression modeling. Separate models for the diagnosis of ACC were developed for male (A, B and C) and female (D, E and F) patients with adrenal tumors. (A) and (D) provide the list of hormones with diagnostic value that have been identified by the model optimization indicated. Akaike Information Criterion (AIC) and area under the curve (AUC) are given. (B) and (E) show receiver operator characteristics (ROC) curved of steroid signatures. (C) and (F) provide the confusion matrix of the selected models: PPV, positive predictive value; NPV, negative predictive value, each for diagnosis of ACC.

References

1

FassnachtMArltWBancosIDralleHNewell-PriceJSahdevATabarinATerzoloMTsagarakisSDekkersOM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology 2016 175 G1G34. (https://doi.org/10.1530/EJE-16-0467)

2

ElseTKimACSabolchARaymondVMKandathilACaoiliEMJollySMillerBSGiordanoTJHammerGD. Adrenocortical carcinoma. Endocrine Reviews 2014 35 282326. (https://doi.org/10.1210/er.2013-1029)

3

FassnachtMKroissMAllolioB. Update in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2013 98 45514564. (https://doi.org/10.1210/jc.2013-3020)

4

BolandGWLeeMJGazelleGSHalpernEFMcNicholasMMMuellerPR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. American Journal of Roentgenology 1998 171 201204. (https://doi.org/10.2214/ajr.171.1.9648789)

5

SzolarDHKammerhuberFH. Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. Radiology 1998 207 369375. (https://doi.org/10.1148/radiology.207.2.9577483)

6

KorobkinMGiordanoTJBrodeurFJFrancisIRSiegelmanESQuintLEDunnickNRHeikenJPWangHH. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996 200 743747. (https://doi.org/10.1148/radiology.200.3.8756925)

7

KebebewEReiffEDuhQYClarkOHMcMillanA. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World Journal of Surgery 2006 30 872878. (https://doi.org/10.1007/s00268-005-0329-x)

8

KerkhofsTMVerhoevenRHVan der ZwanJMDielemanJKerstensMNLinksTPVan de Poll-FranseLVHaakHR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. European Journal of Cancer 2013 49 25792586. (https://doi.org/10.1016/j.ejca.2013.02.034)

9

TerzoloMAngeliAFassnachtMDaffaraFTauchmanovaLContonPARossettoRBuciLSperonePGrossrubatscherE et al. Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 2007 356 23722380. (https://doi.org/10.1056/NEJMoa063360)

10

BerrutiAGrisantiSPulzerAClapsMDaffaraFLoliPMannelliMBoscaroMArvatETiberioG et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2017 102 13581365. (https://doi.org/10.1210/jc.2016-2894)

11

MegerleFHerrmannWSchloetelburgWRonchiCLPulzerAQuinklerMBeuschleinFHahnerSKroissMFassnachtM et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2018 103 16861695. (https://doi.org/10.1210/jc.2017-02591)

12

GowerDBSternMI. Steroid excretion and biosynthesis, with special reference to androst-16-enes, in a woman with a virilising adrenocortical carcinoma. Acta Endocrinologica 1969 60 265275. (https://doi.org/10.1530/acta.0.0600265)

13

GowerDBDalyJRSnodgrassGJSternMI. Steroid excretion and biosynthesis with special reference to C19-delta16-steroids in an infant with a virilizing adrenocortical carcinoma. Acta Endocrinologica 1970 63 562576. (https://doi.org/10.1530/acta.0.0630562)

14

ArltWBiehlMTaylorAEHahnerSLibeRHughesBASchneiderPSmithDJStiekemaHKroneN et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. Journal of Clinical Endocrinology and Metabolism 2011 96 37753784. (https://doi.org/10.1210/jc.2011-1565)

15

KerkhofsTMAKerstensMNKemaIPWillemsTPHaakHR. Diagnostic value of urinary steroid profiling in the evaluation of adrenal tumors. Hormones and Cancer 2015 6 168175. (https://doi.org/10.1007/s12672-015-0224-3)

16

VogeserMParhoferKG. Liquid chromatography tandem-mass spectrometry (LC-MS/MS) – technique and applications in endocrinology. Experimental and Clinical Endocrinology and Diabetes 2007 115 559570. (https://doi.org/10.1055/s-2007-981458)

17

MonaghanPJKeevilBGTrainerPJ. The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Reviews in Endocrine and Metabolic Disorders 2013 14 143157. (https://doi.org/10.1007/s11154-013-9240-1)

18

TaylorDRGhataoreLCouchmanLVincentRPWhitelawBLewisDDiaz-CanoSGalataGSchulteKMAylwinS et al. A 13-steroid serum panel based on LC-MS/MS: use in detection of adrenocortical carcinoma. Clinical Chemistry 2017 63 18361846. (https://doi.org/10.1373/clinchem.2017.277624)

19

Di DalmaziGFanelliFMezzulloMCasadioERinaldiEGarelliSGiampalmaEMosconiCGolfieriRVicennatiV et al. Steroid profiling by LC-MS/MS in nonsecreting and subclinical cortisol-secreting adrenocortical adenomas. Journal of Clinical Endocrinology and Metabolism 2015 100 35293538. (https://doi.org/10.1210/JC.2015-1992)

20

RipleyBVenablesBBatesDMHornikKGebhardtAFirthD. Support Functions and Datasets for Venables and Ripley’s MASS. In http://www.stats.ox.ac.uk/pub/MASS4/2018.

21

BrucePAndrewB. Practical Statistics for Data Scientists. O’Reilly MediaBoston, MA, USA 2017.

22

JamesGWittenDHastieTTibshiraniR. An Introduction to Statistical Learning: With Applications in R. Springer, Inc.2014.

23

SingTSanderOBeerenwinkelNLengauerT. ROCR: visualizing classifier performance in R. Bioinformatics 2005 21 39403941. (https://doi.org/10.1093/bioinformatics/bti623)

24

VanDerWalJFalconiLJanuchowskiSShooLStorlieC. Species Distribution Modelling Tools: Tools for Processing Data Associated With Species Distribution Modelling Exercises. https://CRAN.R-project.org/package=SDMTools2014.

25

ShackletonCH. Congenital adrenal hyperplasia caused by defect in steroid 21-hydroxylase. Establishment of definitive urinary steroid excretion pattern during first weeks of life. Clinica Chimica Acta 1976 67 287298. (https://doi.org/10.1016/0009-8981(76)90337-5)

26

CaulfieldMPLynnTGottschalkMEJonesKLTaylorNFMalunowiczEMShackletonCHReitzREFisherDA. The diagnosis of congenital adrenal hyperplasia in the newborn by gas chromatography/mass spectrometry analysis of random urine specimens. Journal of Clinical Endocrinology and Metabolism 2002 87 36823690. (https://doi.org/10.1210/jcem.87.8.8712)

27

KroneNReischNIdkowiakJDhirVIvisonHEHughesBARoseITO’NeilDMVijzelaarRSmithMJ et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Journal of Clinical Endocrinology and Metabolism 2012 97 E257E267. (https://doi.org/10.1210/jc.2011-0640)

28

KamrathCHartmannMFBoettcherCZimmerKPWudySA. Diagnosis of 21-hydroxylase deficiency by urinary metabolite ratios using gas chromatography-mass spectrometry analysis: reference values for neonates and infants. Journal of Steroid Biochemistry and Molecular Biology 2016 156 1016. (https://doi.org/10.1016/j.jsbmb.2015.10.013)

29

ArltWWalkerEADraperNIvisonHERideJPHammerFChalderSMBorucka-MankiewiczMHauffaBPMalunowiczEM et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004 363 21282135. (https://doi.org/10.1016/S0140-6736(04)16503-3)

30

MinowadaSKinoshitaKHaraMIsurugiKUchikawaTNiijimaT. Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. Endocrinologia Japonica 1985 32 2937. (https://doi.org/10.1507/endocrj1954.32.29)

31

GrondalSErikssonBHagenasLWernerSCurstedtT. Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinologica 1990 122 656663. (https://doi.org/10.1530/acta.0.1220656)

32

KerkhofsTMKerstensMNKemaIPWillemsTPHaakHR. Diagnostic value of urinary steroid profiling in the evaluation of adrenal tumors. Hormones and Cancer 2015 6 168175. (https://doi.org/10.1007/s12672-015-0224-3)

33

ArltWLangKSitchAJDietzASRhayemYBancosIFeuchtingerAChortisVGilliganLCLudwigP et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2017 2 e93136.

Index Card

PubMed

Google Scholar

Related Articles

Altmetrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 343 343 343
Full Text Views 78 78 78
PDF Downloads 49 49 49